secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001193125-26-109511
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues second Complete Response Letter for Aldeyra's reproxalap NDA; efficacy concerns cited
--------------------------------------------------------------------------------

- CRL states 'lack of substantial evidence' and 'failed to demonstrate efficacy' for dry eye disease signs and symptoms.
- No safety or manufacturing concerns identified; FDA did not recommend additional trials or confirmatory evidence.
- Aldeyra intends to request Type A meeting within 30 days to determine next steps for approval.
- Cash and marketable securities of $70M as of Dec 31, 2025 expected to fund operations into 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/0001193125-26-109511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-109511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer